Project Viridian
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Company Profile
Privately held specialty pharmaceutical company advancing
transdermal 505(b)(2) drug programs across large therapeutic markets.
Headquartered in the USA, Viridian combines in-house formulation, development and early-stage testing with an experienced external regulatory, clinical and manufacturing network. The portfolio spans CNS, cardiovascular, metabolic, oncology and autoimmune opportunities.
Investment Highlights
Focused transdermal 505(b)(2) strategy - Programs are built around known APIs and transdermal delivery, targeting differentiated dosing, adherence and product positioning.
Integrated formulation & development platform - In-house transdermal formulation and early-stage testing are supported by external regulatory, clinical and manufacturing partners, enabling efficient advancement from feasibility through scale-up.
Diversified pipeline with lead readiness - Portfolio spans multiple therapeutic areas, with Dapagliflozin and Tizanidine highlighted in clinicals and additional assets in preclinical / development.
Multiple investment & partnering pathways - Company materials cite product investment, clinical partnerships and out-licensing of technology as core strategic opportunities.
Transaction Overview
Seeking investment and strategic partnerships to advance clinical studies and select product opportunities.
Stated opportunities include out-licensing of technology and partnering around individual pipeline assets.
Additional capital and partners can support enhancer studies, regulatory
execution and manufacturing readiness.
Selected Portfolio Snapshot
Dapagliflozin
Brand Name - Farxiga Indication -Type 2 Diabetes/HF
Current Status - Clinicals
Tizanidine
Brand Name - Zanaflex
Indication - Muscle spasms
Current Status - Clinicals
Guanfacine
Brand Name - Intuniv / Tenex
Indication - ADHD / hypertension
Current Status - Preclinical ready
Lenalidomide
Brand Name - Revlimid
Indication - Multiple myeloma
Current Status - Development
Rivaroxaban
Brand Name - Xarelto
Indication - Anticoagulant
Current Status - On hold - enhancer